Email Updates

You are here

Home

HPTN 082

Status
Completed
Phase
Demo Project
Objective

To assess the proportion and characteristics of young HIV-uninfected women who initiate versus do not initiate PrEP at enrollment; to assess the proportion of young women who continue and remain adherent to PrEP at Weeks 13 and 26, based on tenofovir (TFV) levels in plasma and/or dried blood spots (DBS).

Prevention Option(s)
PrEP
Arms and Assigned Interventions
Products
TDF/FTC (Truvada)
Official Code
NCT02732730
Trial Sponsors
Wits RHI, HPTN; DAIDS, NIAID, NIMH
June 2016
August 2018
Enrollment
600
16
Years
25
Years
Population
Women
Sites

Emavundleni (EMA) CRS

Cape Town
South Africa

Wits HIV CRS

Johannesburg, Gauteng
South Africa

Spilhaus Clinical Research Site

Harare
Zimbabwe